Trials / Completed
CompletedNCT00077974
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SU011248 | 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2004-02-18
- Last updated
- 2010-10-13
- Results posted
- 2009-11-03
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00077974. Inclusion in this directory is not an endorsement.